Hanmi Pharmaceutical announced Wednesday it signed an exclusive supply and licensing agreement with Viet Phap, a leading Vietnamese pharmaceutical company, to export several antihypertensive combination drugs to Vietnam.
The agreement was signed during CPHI Worldwide 2025, held at Messe Frankfurt in Frankfurt, Germany, from last Tuesday to Thursday. Hanmi CEO Park Jae-hyun and Viet Phap CEO Nguyen Chi Dung signed the contract, Hanmi said.
Under the agreement, Hanmi Pharmaceutical will supply Viet Phap with finished products of the hypertension combination drug, and Viet Phap will license, distribute, and sell these products within Vietnam.
The two companies will collaborate closely to ensure the successful entry of Hanmi's new drugs into Vietnam.
Viet Phap, a private firm in Hanoi, is recognized as a leader in the Vietnamese pharmaceutical market with over 20 years of R&D. Since its 2002 founding, it has imported and supplied orphan and original drugs in various therapeutic areas.
The Vietnamese hypertension market serves about 15 million patients and is growing at an annual rate of $40 million. Leveraging its expertise, Viet Phap will help Hanmi's flagship drug lineup achieve stable market positioning.
Through this partnership, both companies plan to expand access to hypertension treatments in Vietnam, focusing on unmet needs and a better treatment environment.
“Through our collaboration with Hanmi, we will introduce next-generation treatments to Vietnam, accelerating Viet Phap's growth and contributing to public health,” Viet Phap CEO Nguyen Chi Dung said. “Beyond hypertension, we aim to extend our partnership to products for other unmet needs.”
He added, “I am confident Hanmi’s technology and Viet Phap’s expertise will soon bring innovative treatments to Vietnamese professionals and patients.”
Hanmi CEO Park Jae-hyun said, “This collaboration with Viet Phap lays the foundation for our hypertension therapy to secure a foothold in Vietnam.”
Park added that Hanmi will continue to support and cooperate to ensure Vietnamese patients have access to effective hypertension treatments.
Related articles
- Hanmi Pharm to sell 3 Boehringer COPD inhalers in Korea, including Spiriva and Vahelva
- Hanmi Pharm continues to unveil new anticancer drug pipelines globally
- Hanmi Pharm launches expanded diabetes lineup, Empalon Family
- [ESMO 2025] Hanmi Pharm targets solid tumors with ‘EZH1/2 dual inhibitor’
- Hanmi Science and Hanmi Pharmaceutical get ‘AA-’ rating from NICE
- Hanmi Pharm files FDA IND for obesity drug that targets fat loss and muscle gain
- Hanmi Pharm files phase 3 IND for GLP-1 combo in type 2 diabetes
- Hanmi’s obesity drug that 'adds muscle while losing fat' wins FDA OK for phase 1
- Telminuvo launch highlights shift toward low-dose dual therapy as 1st-line standard in hypertension